Neurocrine Bioscienc
(NQ:
NBIX
)
120.17
-1.04 (-0.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
Next >
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
September 22, 2023
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Analyst Expectations for Neurocrine Biosciences's Future
September 13, 2023
Via
Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
September 13, 2023
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in...
Via
Benzinga
What's Going On With Neurocrine Biosciences Stock Today?
September 12, 2023
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due...
Via
Benzinga
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
September 12, 2023
The company is working on a treatment for a disorder than can cause children to begin puberty early.
Via
Investor's Business Daily
Analyst Ratings for Neurocrine Biosciences
August 21, 2023
Via
Benzinga
Analyst Ratings for Neurocrine Biosciences
August 02, 2023
Via
Benzinga
Earnings Outlook For Neurocrine Biosciences
July 31, 2023
Via
Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
July 06, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
August 21, 2023
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated
Via
Benzinga
Exposures
Product Safety
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
July 06, 2023
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
June 30, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
June 05, 2023
Via
Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
May 08, 2023
Via
Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
May 03, 2023
Via
Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Neurocrine Biosciences's Earnings: A Preview
May 02, 2023
Via
Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
April 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
July 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
May 04, 2023
Via
Benzinga
Expert Ratings for Neurocrine Biosciences
March 30, 2023
Via
Benzinga
Analyst Expectations for Neurocrine Biosciences's Future
March 03, 2023
Via
Benzinga
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
February 06, 2023
Neurocrine also topped fourth-quarter revenue expectations on Monday.
Via
Investor's Business Daily
3 Pharma Stocks That Could See a Surge in Demand in 2023
April 24, 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
March 13, 2023
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
March 03, 2023
Via
Benzinga
Five Best And Worst Performing Healthcare Stocks In January 2023
February 05, 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...
Via
Talk Markets
Earnings Scheduled For February 6, 2023
February 06, 2023
Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.